BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.260
+0.125 (5.85%)
At close: Nov 22, 2024, 4:00 PM
2.300
+0.040 (1.77%)
After-hours: Nov 22, 2024, 5:26 PM EST
BioCardia Revenue
BioCardia had revenue of $71.00K in the twelve months ending September 30, 2024, down -87.54% year-over-year. In the year 2023, BioCardia had annual revenue of $477.00K, down -64.72%.
Revenue (ttm)
$71.00K
Revenue Growth
-87.54%
P/S Ratio
62.78
Revenue / Employee
$3,550
Employees
20
Market Cap
7.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 728.11M |
IM Cannabis | 38.04M |
XWELL | 33.83M |
Ontrak | 11.24M |
Applied DNA Sciences | 3.40M |
Syros Pharmaceuticals | 386.00K |
Soligenix | 364.18K |
Cardio Diagnostics Holdings | 35.69K |
BCDA News
- 9 days ago - BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire
- 3 months ago - FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment - GlobeNewsWire
- 3 months ago - BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results - GlobeNewsWire
- 4 months ago - BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application - GlobeNewsWire